Hoffmann-la Roche Inc.

Roche Glycart Ag

F. Hoffmann-la Roche Ag

Frank Herting

Christian Klein

Ekkehard Moessner

Pablo Umana

Anja Limberg

Georg Fertig

Ulrike Reiff

Manfred Kubbies

Matthias Koerner

Michael Weidner

Ulrich Tibes

Joerg Thomas Regula

Kay-Gunnar Stubenrauch

Matthias Rueth

Harald Duerr

Olaf Mundigl

Peter Bruenker

Tilman Schlothauer

Carola Ries

Adelbert Grossmann

Klaus-Peter Kuenkele

Michael Jarsch

Thomas Friess

Sabine Hoves

Sylvia Herter

Katharina Wartha

Charles Dumontet

Anton Haselbeck

Piergiorgio Francesco Tommaso Pettazzoni

Markus Dangl

Juergen Wichmann

Jan Eckmann

Joerg Huwyler

The present invention relates to modified antibodies. In particular, the present invention relates to recombinant monoclonal antibodies having altered ability to induce direct cell death and effector function. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention, and to methods of using these antibodies in treatment of disease.

Antibody fab and Fc variants

The present invention relates to the combination therapy of specific antibodies which bind human CSF-1R with specific antibodies which bind human PD-L1.

Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1

The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases

Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer. 

Hydroxamates, their manufacture and use as pharmaceutical agents

Mono-acylated o-phenylendiamines derivatives of formula A: which are useful for the treatment of diseases mediated by the inhibition of histone deacetylase, such as cancer.

Mono-acylated o-phenylendiamines derivatives

Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer. 

Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors

Thiophene derivatives, their manufacture and use as pharmaceutical agents

Mono-acylated o-phenylendiamines derivatives of formula I wherein X and R are as described herein, have been found useful for the treatment of diseases mediated by the inhibition of histone deacetylase, such as cancer.

N-monoacylated o-phenylenediamines

The present invention relates to compounds of formula I, their pharmaceutically acceptable salts as well as their enantiomeric forms, diastereoisomers and racemates; the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds as inhibitors of histone deacetylase (HDAC) and therefore in the control or prevention of illnesses and disorders as mentioned above, or in the manufacture of corresponding pharmaceutical compositions.

Oxime derivatives and their use as pharmaceutically active agents

The present invention describes compounds of the general formula I as well as processes for their manufacture, pharmaceutical compositions containing them and methods for using these compounds and pharmaceutical compositions as pharmaceutical agents. The compounds according to this invention show antiproliferative and differentiation-inducing activity, which results in inhibition of tumor cell proliferation, induction of apoptosis and inhibition of invasion.

Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives

The (R) and (S) enantiomers of a compound of formula I are novel antiproliferative therapeutic agents. These compounds have HDAC inhibitor activity and are useful in the treatment of cancer. Also disclosed are methods of making and using compounds of formula (I), as well as pharmaceutical compositions containing compounds of formula (I).

Thiophene hydroxamic acid derivatives

Mono-acylated o-phenylendiamines derivatives of formula A wherein Ar, R, and Rare as described herein, have been found useful for the treatment of diseases mediated by the inhibition of histone deacetylase, such as cancer.

Growing community of inventors

Penzberg, Germany

Frank Herting